Menu
Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 3
Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
Authors Gopalakrishnan S, Tan D
Received 23 January 2013
Accepted for publication 12 March 2013
Published 18 April 2013 Volume 2013:3 Pages 19—24
DOI https://doi.org/10.2147/BLCTT.S29567
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Sathish Gopalakrishnan,1 Daryl Tan1,2
1Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore; 2Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore
Abstract: Although the clinical outcomes of patients with multiple myeloma has improved tremendously with the advent of bortezomib and immunomodulatory drugs like thalidomide and lenalidomide, the disease remains incurable and patients will eventually be resistant to these drugs. Novel non-cross-resistant modalities of treatment are needed. Immunotherapy is potentially a very promising therapeutic modality for further development. Daratumumab is a novel, high-affinity, therapeutic human monoclonal antibody against a unique CD38 epitope. It induces tumor-cell killing through several immunological mechanisms. It has shown a favorable safety profile as monotherapy and significant single-agent activity in relapsed/refractory myeloma. It has also demonstrated strong synergism with lenalidomide and bortezomib. The potential of this agent, together with its pharmacokinetics, mode of action, early efficacy, and safety data will be detailed in this review.
Keywords: daratumumab, myeloma, monoclonal
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.